Gf Fund Management Co. Ltd. Janux Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $4.26 Trillion
- Q1 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,343 shares of JANX stock, worth $31,694. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,343
Previous 1,102
21.87%
Holding current value
$31,694
Previous $59 Million
38.54%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
193Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$264 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$109 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$86.2 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$78.6 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$55.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $983M
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...